KMLE
»çÀÌÆ® ¼Ò°³
°Ë»ö
°Ë»ö¾î Áö¿ì±â
´Ý±â
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
°í±Þ °Ë»ö ¼³Á¤
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
psychedelic drug
ȯ°¢Á¦(ü³ÊÆð¥)
reduced substrate concentration
ȯ»ê ±âÁú ³óµµ(üµß©Ñ¨òõÒØÓø)
reduced scattered light intensity
ȯ»ê »ê¶õ±¤ °µµ(üµß©ß¤Õ¯ÎÃËÓø)
reduced osmotic pressure
ȯ»ê »ïÅõ¾Ð(üµß©ß¶÷âäâ)
reduced viscosity
ȯ»ê Á¡µµ(üµß©ïÄÓø)
reduced mean residue rotation
ȯ»ê Æò±Õ Àܱâ ȸÀü(üµß©øÁгíÑÐñüÞï®)
toroidal supercoil
ȯ»ó(ü»ßÒ)¼öÆÛÄÚÀÏ
annulation reaction
ȯ»óÇü¼º ¹ÝÀÀ(ü»ßÒû¡à÷Úãëë)
reducing equivalent
ȯ¿ø ´ç·®(ü½êªÓ×Õá)
reducing agent
ȯ¿ø ½Ã¾à(ü½êªãËå·)
reduction potential
ȯ¿ø ÀüÀ§(ü½êªï³êÈ)
reduction phase
ȯ¿ø±â(ü½êªÑ¢)
reducing sugar
ȯ¿ø´ç(ü½êªÓØ)
reducing power
ȯ¿ø·Â(ü½êªÕô)
reducing atmosphere
ȯ¿ø¼º ´ë±â(ü½êªàõÓÞѨ)
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
acetate-replacing factor
¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í)
alkali disease
¾ËÄ®¸®¼ºÁúȯ(òðü´)
allogeneic disease
µ¿Á¾ÀÌÀÎÀÚÇü Áúȯ(ÔÒðúì¶ì×íúþ òðü´)
amino acid substitution
¾Æ¹Ì³ë»ê ġȯ(öÇüµ)
anion exchanger
À½(ëä)À̿ ±³È¯Á¦(Îßüµð¥)
antigenic conversion
Ç׿øÀüȯ(ù÷ê«ï®üµ)
assimilatory reduction
µ¿ÈÀûȯ¿ø (ÔÒûùîÜü½êª)
autoallergic disease
ÀÚ°¡(í»Ê«)¾Ë·¹¸£±â Áúȯ(òðü´)
autoimmune disease
ÀÚ°¡¸é¿ªÁúȯ (í»Ê«Øóæ¹òðü´)
Balbiani ring
¹ßºñ¾Æ´Ï ȯ(ü»)
base-pair substitution
¿°±â¦ ġȯ(öÇüµ)
base substitution
¿°±âġȯ(ç¤ÐñöÇüµ)
biological oxidation-reduction
»ýü »êÈȯ¿ø(ßæô÷ß«ûùü½êª)
biotope
»ýüȯ°æ(ßæô÷ü»ÌÑ)
biotransformation
»ýüº¯È¯(ßæô÷ܨüµ)
´ÙÀ½
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½